A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma

Abstract

BackgroundThe therapeutic effect of immune checkpoint blockers, especially the neutralizing antibodies of programmed cell death (PD-1) and its ligand programmed death ligand 1 (PD-L1), has been well verified in melanoma. Nevertheless, the dissatisfactory response rate and the occurrence of resistance significantly hinder the treatment effect. Inflammation-related molecules like A20 are greatly implicated in cancer immune response, but the role of tumorous A20 in antitumor immunity and immunotherapy efficacy remains elusive.MethodsThe association between tumorous A20 expression and the effect of anti-PD-1 immunotherapy was determined by immunoblotting, immunofluorescence staining and flow cytometry analysis of primary tumor specimens from melanoma patients. Preclinical mouse model, in vitro coculture system, immunohistochemical staining and flow cytometry analysis were employed to investigate the role of A20 in regulating the effect of anti-PD-1 immunotherapy. Bioinformatics, mass spectrum analysis and a set of biochemical analyzes were used to figure out the underlying mechanism.ResultsWe first discovered that upregulated A20 was associated with impaired antitumor capacity of CD8+T cells and poor response to anti-PD-1 immunotherapy in melanoma patients. Subsequent functional studies in preclinical mouse model and in vitro coculture system proved that targeting tumorous A20 prominently improved the effect of immunotherapy through the invigoration of infiltrating CD8+T cells via the regulation of PD-L1. Mechanistically, A20 facilitated the ubiquitination and degradation of prohibitin to potentiate STAT3 activation and PD-L1 expression. Moreover, tumorous A20 expression was highly associated with the ratio of Ki-67 percentage in circulating PD-1+CD8+T cells to tumor burden.ConclusionsTogether, our findings uncover a novel crosstalk between inflammatory molecules and antitumor immunity in melanoma, and highlight that A20 can be exploited as a promising target to bring clinical benefit to melanomas refractory to immune checkpoint blockade.

Recent applications of quantitative systems pharmacology and machine learning models across diseases

“…They predict that the efficacy of treatment is dictated by the patient’s variability and unique characteristics. This model not only aids TCEs and immune checkpoint strategies but also is an interesting tool for precision medicine initiatives [ 39 ].…”

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma

“…However, patients usually developed refractory; then, the second-line therapy was varied and disappointed ( Sirica et al, 2019 ). PD-1 inhibitor-based immune therapy has obtained significant improvement in several tumors, including melanoma, lung cancer, and head and neck malignancies ( Sui et al, 2018 ; Gavrielatou et al, 2020 ; Guo et al, 2020 ). However, immune monotherapy faces many challenges in biliary cancer.…”

Hepatitis B Virus-Associated Follicular Lymphoma Reveals T-Cell Inflamed Phenotype and Response to Lenalidomide

“…Among these mutations in immune modulators, TNFAIP3 and KLF2 are implicated in negative regulation of in ammation through counteracting NF-κB activation [43,44]. TNFAIP3 de ciency increases in ltration of CD8 + T cells in melanoma [44,45]. and knockout of KLF2 enhances T cell activation and immune response [46].…”